Johnson & Johnson asked the district judge overseeing the federal lawsuit against its vaginal mesh devices to investigate phone calls urging women with the implant to file suit against the company.
HeartWare announced the first implant of its HeartWare Ventricular Assist System and HVAD Pump using the less-invasive thoracotomy procedure in patients with its HVAD Lateral clinical trial of end-stage heart failure patients who are waiting for a heart transplant.
Weeks after a federal judge encouraged C.R. Bard to resolve thousands of pending lawsuits over its vaginal mesh implants, the company is requesting a delay of its product liability trial, arguing that the judge's comments regarding a potential settlement may have prejudiced the jury pool.
GlySens will use a $12 million Series C financing to conduct a clinical trial for a second iteration of its receiver and implantable sensor that enable continuous glucose monitoring for diabetic patients.
Catheter-based peripheral artery disease treatment company Avinger filed with the SEC to raise up to $69 million, while molecular diagnostics player HTG Molecular Diagnostics filed to raise up to $60 million. In addition, orthopedic regenerative medicine player CollPlant is reportedly seeking a listing on a U.S. market; it is already listed publicly in Israel.
A U.S. federal appeals court cut the patent infringement damages that Zimmer must pay to Stryker from $228 million to $70 million, overruling a previous decision that found the infringement was willful.
Chicago-based private equity group First Analysis expects its $12 million cash infusion into Sonoma Orthopedic Products will be sufficient for the startup to gain FDA clearance for a new ankle implant--as well as to launch it and start to scale up sales.
After recent courtroom losses for Johnson & Johnson and Boston Scientific in cases involving vaginal mesh implants, a federal judge encouraged C.R. Bard to settle the thousands of similar lawsuits it faces. In doing so, he cited the responsibility of the company to its shareholders to limit losses, according to a Bloomberg article.
St. Jude Medical has gained approval for a quadripolar cardiac resynchronization therapy pacemaker that for the first time incorporates its MultiPoint Pacing technology that's been shown to be better for patients who don't respond to traditional biventrical pacing.
SetPoint Medical is starting a clinical trial to treat Crohn's disease patients with its implantable neuromodulation device. The startup previously reported a positive pilot study of the device to treat rheumatoid arthritis.